An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Asthma Clinical Trial

— DEAR  

Official title:

Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-Week, Placebo-Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computer Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02937168
• Other study ID #: C38072-AS-40105
• Status: Terminated
• Phase: Phase 4
• Start date: May 8, 2017
• Est. completion date: May 24, 2017

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in participants with severe asthma and an eosinophilic phenotype .

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: May 24, 2017
• Est. primary completion date: May 24, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male or female, 18 through 50 years of age.

• Females that are either surgically sterile, are 2 years postmenopausal, or have a negative pregnancy test at screening.

• Females of childbearing potential (not surgically sterile or 2 years postmenopausal), have to use a medically accepted method of contraception and have to agree to continue to use of this method for the duration of the study and for 5 months after study drug administration.

• Participants with less that 10-pack year history of smoking.

• Have a previous diagnosis of asthma.

• Participants taking inhaled fluticasone at a dosage of at least 440 micrograms (mcg) daily, or equivalent.

• The participant's baseline asthma therapy must be stable for 30 days prior to screening and judged by their treating physician to be able to continue without dosage changes throughout the study.

• Participants with a blood eosinophil level of at least 400 cells/microliter (cells/µL) at screening. Participants with a blood eosinophil level below 400 cells/µL will be given 2 additional screening opportunities to determine blood eosinophil levels.

• Additional criteria apply; please contact the investigator for more information.

Exclusion Criteria:

• Participants requiring treatment with oral, intramuscular, or IV corticosteroids within 6 weeks of the Part 1 baseline visit for an asthma exacerbation.

• Participants with any other confounding underlying lung disorder including but not limited to: bronchiectasis, chronic obstructive pulmonary disorder, smoking greater than or equal to (=)10 pack year history, pulmonary fibrosis, emphysema, cystic fibrosis, and lung cancer.

• Participants diagnosed with diabetes mellitus.

• Participants with pulmonary conditions and blood eosinophilia other than eosinophilic asthma.

• Participants with clinically meaningful comorbidity that can interfere with the study schedule or procedures, or compromise the participant's safety.

• Participants that are current smokers (that is, have smoked within the last 12 months prior to screening).

• Participants using systemic immunosuppressive, immunomodulating, or other biologic agents (including, but not limited to, anti-IgE mAb, methotrexate, cyclosporin, interferon-a, or anti-tumor necrosis factor mAb) within 6 months prior to screening. Participants whose treatment with anti-IgE mAb therapy (omalizumab) is considered ineffective by their physician may be included as potential participants when:

1. The omalizumab (Xolair) therapy has been discontinued.

2. The participant's blood eosinophil level meets inclusion criteria.

• Participants who have previously received an anti-hIL-5 mAb (for example, reslizumab, mepolizumab [Nucala]) or anti-IL-5 receptor mAb (eg, benralizumab). Participants whose treatment with mepolizumab or benralizumab is considered ineffective by their physician may be included as potential participants when:

1. The mepolizumab or benralizumab therapy has been discontinued.

2. The participant's blood eosinophil level meets inclusion criteria.

• Participants who had concurrent infection or disease that may preclude assessment of active asthma.

• Participants with a history of concurrent immunodeficiency (human immunodeficiency virus or acquired immunodeficiency syndrome or congenital immunodeficiency).

• Participants that had an active parasitic infection within 6 months prior to screening.

• Participants with any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).

• Known hypersensitivity to study drug or to FDG/contrast agents

• Treatment with metformin.

• Compromised renal function.

• Additional criteria apply; please contact the investigator for more information.

Related Conditions & MeSH terms

• Asthma
• Inflammation

Intervention

Drug:
• Reslizumab
Reslizumab will be administered as per the dose and schedule specified in the arm.
• Fludeoxyglucose F 18 (FDG)
FDG will be administered by IV infusion prior to each PET/CT scan.
• Placebo
Placebo matching to reslizumab will be administered as per the schedule specified in the arm.

Locations

Country	Name	City	State
United States	Teva Investigational Site 13808	New Brunswick	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1)	GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung boundary in each axial slice. Standardized uptake value (SUV) mean and area of each ROI was recorded. Using the formula: area*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported.	Baseline (Day 1) of Part 1
Primary	Part 1: Average Global Lung Glycolysis (GLG) at Day 8	GLG is the total FDG uptake in the whole lung. ROI was drawn around lung boundary in each axial slice. SUV mean and area of each ROI was recorded. Using the formula: area*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported.	Day 8
Primary	Part 2: Change From Baseline to Week 4 in GLG		Baseline, Week 4
Primary	Part 2: Change From Baseline to Week 4 in Lung Parenchyma (LP) SUV Mean		Baseline, Week 4
Secondary	Part 2: Change From Baseline to Week 4 in Blood Eosinophil Counts		Baseline, Week 4
Secondary	Change From Baseline to Week 4 in Forced Expiratory Volume in 1 Second (FEV1)		Baseline, Week 4
Secondary	Change From Baseline to Week 4 in Fractional Exhaled Nitric Oxide (FeNO)		Baseline, Week 4
Secondary	Change From Baseline to Week 4 in Asthma Quality of Life Questionnaire (AQLQ) Score		Baseline, Week 4
Secondary	Number of Participants With Adverse Events (AEs)	An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.	21 days